EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Serum/Xeno‐Free Medium and Cytokine Supplementation on CAR‐T Cell Therapy Manufacturing in Stirred Tank Bioreactors

Pedro Silva Couto iD, Dale J Stibbs, Pierre Springuel, Ursula Schultz, Manuel Effenberger, Stephen Goldrick iD, Sergio Navarro-Velázquez, Manel Juan, Laura Herbst, Bastian Nießing, Katrin Mestermann, Carmen Sanges und 2 weitere

Biotechnology Journal · 2025

DOI: 10.1002/biot.70114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2025. Verfasst von Pedro Silva Couto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Engineering, University College London, London, UK. Hauptthemen laut MEDLINE: Bioreactors, Cytokines, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCL's Cell and Gene Therapy Therapeutic Innovation Networks (TINs) as part of the Wellcome Trust Translational Partnership Award, Engineering and Physical Sciences Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T‐cell (CAR‐T) therapies have demonstrated clinical efficacy in treating haematological malignancies, resulting in multiple regulatory approvals. However, there is a need for robust manufacturing platforms and the use of GMP‐aligned reagents to meet the clinical and commercial demands. This study investigates the impact of serum/xeno‐free medium (SXFM) and cytokine supplementation on CAR‐T cell production in static and agitated culture systems, using 24‐well plate G‐Rex vessels and 500 mL stirred tank bioreactors (STRs), respectively. Under static conditions, SXFM media supported CAR‐T cell expansion with growth kinetics comparable to foetal bovine serum, FBS‐based RPMI, irrespective of the cytokine supplementation (IL‐2 or the combination of IL‐7 and IL‐15). In contrast, when the expansion was conducted using STRs, several differences were observed with SXFM. Particularly, when supplemented with IL‐2 SXFM, it increased transduction efficiency, supporting accelerated proliferation relative to FBS‐containing RPMI. Additionally, SXFM maintained a higher CD4:CD8 ratio at harvest, a feature associated with improved clinical outcomes. No significant differences were observed in the CAR‐T cell populations' differentiation status or activation and exhaustion profiles across the conditions. These results suggest that SXFM enables CAR‐T cell manufacturing in STRs, improving key quality attributes such as transduction efficiency, growth kinetics, and CD4:CD8 ratio compared to FBS‐supplemented medium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BioreactorsCytokinesReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesHumansCell ProliferationCulture Media, Serum-FreeCell Culture TechniquesInterleukin-2Culture Media

Stichwörter der Autor:innen

ATMPCAR‐TGMPbiomanufacturingserum freestirred‐tank bioreactorxeno‐free

Substanzen

CytokinesReceptors, Chimeric AntigenCulture Media, Serum-FreeInterleukin-2Culture Media

Autor:innen und Institutionen

  • Department of Biochemical Engineering, University College London, London, UK.
  • Sartorius CellGenix GmbH, Freiburg im Breisgau, Germany.
  • Immunology Department - Immunotherapy Section, Hospital Clínic Barcelona, Barcelona, Spain.
  • Fundació De Recerca Clínic Barcelona-Institut D'investigacions Biomèdiques August Pi i Sunyer (FCRB-IDIBAPS), Barcelona, Spain.
  • HSJD-Clínic Immunotherapy Platform, Barcelona, Spain.
  • Fraunhofer Institute for Production Technology IPT, Aachen, Germany.

ORCID-Profile: Pedro Silva Couto, Stephen Goldrick

Förderung

  • UCL's Cell and Gene Therapy Therapeutic Innovation Networks (TINs) as part of the Wellcome Trust Translational Partnership Award
  • Engineering and Physical Sciences Research Council
  • Wellcome Trust
  • European Commission

Zitieren

APA

Silva Couto, P., Stibbs, D. J., Springuel, P., Schultz, U., Effenberger, M., Goldrick, S., Navarro-Velázquez, S., Juan, M., Herbst, L., Nießing, B., Mestermann, K., Sanges, C., Hudecek, M., & Rafiq, Q. A. (2025). Impact of Serum/Xeno‐Free Medium and Cytokine Supplementation on CAR‐T Cell Therapy Manufacturing in Stirred Tank Bioreactors. Biotechnology Journal. https://doi.org/10.1002/biot.70114

Vancouver

Silva Couto P, Stibbs DJ, Springuel P, Schultz U, Effenberger M, Goldrick S, et al. Impact of Serum/Xeno‐Free Medium and Cytokine Supplementation on CAR‐T Cell Therapy Manufacturing in Stirred Tank Bioreactors. Biotechnology Journal. 2025. doi:10.1002/biot.70114

BibTeX
@article{SilvaCouto2025,
  author = {Silva Couto, Pedro and Stibbs, Dale J and Springuel, Pierre and Schultz, Ursula and Effenberger, Manuel and Goldrick, Stephen and Navarro-Velázquez, Sergio and Juan, Manel and Herbst, Laura and Nießing, Bastian and Mestermann, Katrin and Sanges, Carmen and Hudecek, Michael and Rafiq, Qasim A},
  title = {Impact of Serum/Xeno‐Free Medium and Cytokine Supplementation on CAR‐T Cell Therapy Manufacturing in Stirred Tank Bioreactors},
  journal = {Biotechnology Journal},
  year = {2025},
  doi = {10.1002/biot.70114}
}
Kostenlos starten →